knowledge -WSS

knowledge

author：focus 2025-09-07 11:11:55 - browse：2591

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Synthetic human embryos? Researchers say term is overblown

focus

hotspot

WSS

Ukrainian soldiers say they owe lives to US

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

ADA: All diabetes patients should be screened for liver condition

Belarusian journalist sentenced to 4 years in prison as crackdown continues

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

explore

knowledge

explore

Medicare proposal to cover medical devices draws a mixed reaction

Food makers to regulators: Ultra

BioMarin wins approval for gene therapy to treat hemophilia A

Hospitals consider fixing cancer drug shortages on their own

United colonoscopy coverage change 'may cost lives,' doctors say

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

The cancer drug shortage isn’t new — and neither are the solutions

Food makers tried to stack nutrition panel with preferred experts

Guidelines to prevent youth baseball injuries need more muscle

Walmart eyes Medicare Advantage provider ChenMed

explore

FDA approves updated Covid vaccines

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Popular nasal decongestant doesn't actually relieve congestion

Here's how to stay safe from wildfire smoke amid reduced air quality

How to make the FDA’s new prescription one

leisure time

focus

hotspot

leisure time